Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

Read More Below

Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.
Read more

Contact Us

Thank you for your interest. Shire US welcomes your comments and questions.

Patients and caregivers

Call the Shire Customer Service Center toll-free at 1-800-828-2088, Monday through Friday, 8:30 AM to 5:00 PM ET.

Health care professionals

Clinical inquiries: For further clinical information on Shire products, US health care professionals may call Shire Medical Information toll-free at 1-800-828-2088 or send an e-mail to medinfoglobal@shire.com.